CFTR and cystic fibrosis: CRISPR-based gene editing approaches have been explored to correct certain CFTR mutations in cultured airway basal cells, iPS cells, and advanced cellular models, such as organoid cultures derived from patients with CF (Ensinck et al., 2021; Lee et al., 2021).